1. Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology 2013;58:1497-1507.
[CROSSREF] [PUBMED]
2. Nassir F, Ibdah JA. Role of mitochondria in alcoholic liver disease. World J Gastroenterol 2014;20:2136-2142.
[CROSSREF] [PUBMED] [PMC]
3. Wei YH, Chen YS, Lee JF, Huang JY, Lee CH. Effect of ethanol intake on rat liver mitochondrial respiration and oxidative phosphorylation. Proc Natl Sci Counc Repub China B 1990;14:61-68.
[PUBMED]
4. Einer C, Hohenester S, Wimmer R, Wottke L, Artmann R, Schulz S, et al. Mitochondrial adaptation in steatotic mice. Mitochondrion 2018;40:1-12.
[CROSSREF] [PUBMED]
5. Yi HS, Chang JY, Shong M. The mitochondrial unfolded protein response and mitohormesis: a perspective on metabolic diseases. J Mol Endocrinol 2018;61:R91-R105.
[CROSSREF] [PUBMED] [PMC]
6. Gariani K, Menzies KJ, Ryu D, Wegner CJ, Wang X, Ropelle ER, et al. Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice. Hepatology 2016;63:1190-1204.
[CROSSREF] [PUBMED]
7. Chung HK, Kim JT, Kim HW, Kwon M, Kim SY, Shong M, et al. GDF15 deficiency exacerbates chronic alcohol- and carbon tetrachloride-induced liver injury. Sci Rep 2017;7:17238
[CROSSREF] [PDF]
8. Ciapaite J, Bakker SJ, Van Eikenhorst G, Wagner MJ, Teerlink T, Schalkwijk CG, et al. Functioning of oxidative phosphorylation in liver mitochondria of high-fat diet fed rats. Biochim Biophys Acta 2007;1772:307-316.
[CROSSREF] [PUBMED]
9. Garcia-Ruiz I, Solis-Munoz P, Fernandez-Moreira D, Grau M, Colina F, Munoz-Yague T, et al. High-fat diet decreases activity of the oxidative phosphorylation complexes and causes nonalcoholic steatohepatitis in mice. Dis Model Mech 2014;7:1287-1296.
[CROSSREF] [PUBMED] [PMC]
10. Pospisilik JA, Knauf C, Joza N, Benit P, Orthofer M, Cani PD, et al. Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell 2007;131:476-491.
[CROSSREF]
11. Mansouri A, Gaou I, De Kerguenec C, Amsellem S, Haouzi D, Berson A, et al. An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice. Gastroenterology 1999;117:181-190.
[CROSSREF] [PUBMED]
12. Knockaert L, Berson A, Ribault C, Prost PE, Fautrel A, Pajaud J, et al. Carbon tetrachloride-mediated lipid peroxidation induces early mitochondrial alterations in mouse liver. Lab Invest 2012;92:396-410.
[CROSSREF] [PUBMED] [PDF]
13. Tian Y, Garcia G, Bian Q, Steffen KK, Joe L, Wolff S, et al. Mitochondrial stress induces chromatin reorganization to promote longevity and UPR(mt). Cell 2016;165:1197-1208.
[CROSSREF] [PUBMED] [PMC]
14. Aldridge JE, Horibe T, Hoogenraad NJ. Discovery of genes activated by the mitochondrial unfolded protein response (mtUPR) and cognate promoter elements. PLoS One 2007;2:e874.
[CROSSREF] [PUBMED] [PMC]
15. Cappello F, Marino Gammazza A, Palumbo Piccionello A, Campanella C, Pace A, Conway de Macario E, et al. Hsp60 chaperonopathies and chaperonotherapy: targets and agents. Expert Opin Ther Targets 2014;18:185-208.
[CROSSREF] [PUBMED]
16. Rakonczay Z Jr, Boros I, Jarmay K, Hegyi P, Lonovics J, Takacs T. Ethanol administration generates oxidative stress in the pancreas and liver, but fails to induce heat-shock proteins in rats. J Gastroenterol Hepatol 2003;18:858-867.
[CROSSREF] [PUBMED]
17. Pei W, Tanaka K, Huang SC, Xu L, Liu B, Sinclair J, et al. Extracellular HSP60 triggers tissue regeneration and wound healing by regulating inflammation and cell proliferation. NPJ Regen Med 2016;1:16013
[CROSSREF] [PUBMED] [PMC] [PDF]
18. Yuan D, Huang S, Berger E, Liu L, Gross N, Heinzmann F, et al. Kupffer cell-derived TNF triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS. Cancer Cell 2017;31:771-789.
[CROSSREF] [PUBMED]
19. Wheeler MC, Gekakis N. Hsp90 modulates PPARγ activity in a mouse model of nonalcoholic fatty liver disease. J Lipid Res 2014;55:1702-1710.
[CROSSREF] [PUBMED] [PMC]
20. Rodriguez-Suarez E, Duce AM, Caballeria J, Martinez Arrieta F, Fernandez E, Gomara C, et al. Non-alcoholic fatty liver disease proteomics. Proteomics Clin Appl 2010;4:362-371.
[CROSSREF] [PUBMED] [PMC]
21. Ko KS, Tomasi ML, Iglesias-Ara A, French BA, French SW, Ramani K, et al. Liver-specific deletion of prohibitin 1 results in spontaneous liver injury, fibrosis, and hepatocellular carcinoma in mice. Hepatology 2010;52:2096-2108.
[CROSSREF] [PUBMED] [PMC]
22. Fan W, Yang H, Liu T, Wang J, Li TW, Mavila N, et al. Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells. Hepatology 2017;65:1249-1266.
[CROSSREF] [PUBMED] [PMC]
23. Bruce CR, Carey AL, Hawley JA, Febbraio MA. Intramuscular heat shock protein 72 and heme oxygenase-1 mRNA are reduced in patients with type 2 diabetes: evidence that insulin resistance is associated with a disturbed antioxidant defense mechanism. Diabetes 2003;52:2338-2345.
[CROSSREF] [PUBMED]
24. Levada K, Guldiken N, Zhang X, Vella G, Mo FR, James LP, et al. Hsp72 protects against liver injury via attenuation of hepatocellular death, oxidative stress, and JNK signaling. J Hepatol 2018;68:996-1005.
[CROSSREF] [PUBMED]
25. Quiros PM, Ramsay AJ, Sala D, Fernandez-Vizarra E, Rodriguez F, Peinado JR, et al. Loss of mitochondrial protease OMA1 alters processing of the GTPase OPA1 and causes obesity and defective thermogenesis in mice. EMBO J 2012;31:2117-2133.
[CROSSREF] [PUBMED] [PMC]
26. Romanello V, Sandri M. Mitochondrial quality control and muscle mass maintenance. Front Physiol 2016;6:422
[CROSSREF] [PUBMED] [PMC]
27. Tezze C, Romanello V, Desbats MA, Fadini GP, Albiero M, Favaro G, et al. Age-associated loss of OPA1 in muscle impacts muscle mass, metabolic homeostasis, systemic inflammation, and epithelial senescence. Cell Metab 2017;25:1374-1389.
[CROSSREF] [PUBMED] [PMC]
28. Sood A, Jeyaraju DV, Prudent J, Caron A, Lemieux P, McBride HM, et al. A mitofusin-2-dependent inactivating cleavage of Opa1 links changes in mitochondria cristae and ER contacts in the postprandial liver. Proc Natl Acad Sci U S A 2014;111:16017-16022.
[CROSSREF] [PUBMED] [PMC]
29. Lee HJ, Chung K, Lee H, Lee K, Lim JH, Song J. Downregulation of mitochondrial lon protease impairs mitochondrial function and causes hepatic insulin resistance in human liver SK-HEP-1 cells. Diabetologia 2011;54:1437-1446.
[CROSSREF] [PUBMED] [PDF]
30. Bakala H, Delaval E, Hamelin M, Bismuth J, Borot-Laloi C, Corman B, et al. Changes in rat liver mitochondria with aging. Lon protease-like reactivity and N(epsilon)-carboxymethyllysine accumulation in the matrix. Eur J Biochem 2003;270:2295-2302.
[CROSSREF] [PUBMED]
31. Bhaskaran S, Pharaoh G, Ranjit R, Murphy A, Matsuzaki S, Nair BC, et al. Loss of mitochondrial protease ClpP protects mice from diet-induced obesity and insulin resistance. EMBO Rep 2018;19:e45009.
[CROSSREF] [PUBMED] [PMC]
32. Durieux J, Wolff S, Dillin A. The cell-non-autonomous nature of electron transport chain-mediated longevity. Cell 2011;144:79-91.
[CROSSREF] [PUBMED] [PMC]
33. Markan KR, Naber MC, Ameka MK, Anderegg MD, Mangelsdorf DJ, Kliewer SA, et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 2014;63:4057-4063.
[CROSSREF] [PUBMED] [PMC]
34. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007;5:426-437.
[CROSSREF] [PUBMED]
35. Kim KH, Jeong YT, Oh H, Kim SH, Cho JM, Kim YN, et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med 2013;19:83-92.
[CROSSREF] [PUBMED] [PDF]
36. Berglund ED, Li CY, Bina HA, Lynes SE, Michael MD, Shanafelt AB, et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009;150:4084-4093.
[CROSSREF] [PUBMED] [PMC] [PDF]
37. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009;58:250-259.
[CROSSREF] [PUBMED] [PMC]
38. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007;148:774-781.
[CROSSREF] [PUBMED] [PDF]
39. Zhu S, Ma L, Wu Y, Ye X, Zhang T, Zhang Q, et al. FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK-SIRT1 pathway. Acta Biochim Biophys Sin (Shanghai) 2014;46:1041-1048.
[CROSSREF] [PUBMED] [PDF]
40. Liu Y, Zhao C, Xiao J, Liu L, Zhang M, Wang C, et al. Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury. Sci Rep 2016;6:31026
[CROSSREF] [PUBMED] [PMC] [PDF]
41. Fisher FM, Chui PC, Nasser IA, Popov Y, Cunniff JC, Lundasen T, et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology 2014;147:1073-1083.
[CROSSREF] [PUBMED] [PMC]
42. Xu P, Zhang Y, Liu Y, Yuan Q, Song L, Liu M, et al. Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways. Toxicol Appl Pharmacol 2016;290:43-53.
[CROSSREF] [PUBMED]
43. Kharitonenkov A, Dunbar JD, Bina HA, Bright S, Moyers JS, Zhang C, et al. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol 2008;215:1-7.
[CROSSREF] [PUBMED]
44. Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, Goetz R, et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A 2007;104:7432-7437.
[CROSSREF] [PUBMED] [PMC]
45. Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, Wang L, et al. Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult Mouse. Mol Endocrinol 2010;24:2050-2064.
[CROSSREF] [PUBMED] [PMC] [PDF]
46. Breit SN, Johnen H, Cook AD, Tsai VW, Mohammad MG, Kuffner T, et al. The TGF-β superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 2011;29:187-195.
[CROSSREF]
47. Chung HK, Ryu D, Kim KS, Chang JY, Kim YK, Yi HS, et al. Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis. J Cell Biol 2017;216:149-165.
[CROSSREF] [PUBMED] [PMC] [PDF]
48. Li D, Zhang H, Zhong Y. Hepatic GDF15 is regulated by CHOP of the unfolded protein response and alleviates NAFLD progression in obese mice. Biochem Biophys Res Commun 2018;498:388-394.
[CROSSREF] [PUBMED]
49. Zimmers TA, Jin X, Hsiao EC, Perez EA, Pierce RH, Chavin KD, et al. Growth differentiation factor-15: induction in liver injury through p53 and tumor necrosis factor-independent mechanisms. J Surg Res 2006;130:45-51.
[CROSSREF] [PUBMED]
50. Koo BK, Um SH, Seo DS, Joo SK, Bae JM, Park JH, et al. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease. Liver Int 2018;38:695-705.
[CROSSREF] [PUBMED]
51. Kim KH, Kim SH, Han DH, Jo YS, Lee YH, Lee MS. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice. Sci Rep 2018;8:6789
[CROSSREF] [PUBMED] [PMC] [PDF]
52. Zhang M, Sun W, Qian J, Tang Y. Fasting exacerbates hepatic growth differentiation factor 15 to promote fatty acid β-oxidation and ketogenesis via activating XBP1 signaling in liver. Redox Biol 2018;16:87-96.
[CROSSREF] [PUBMED] [PMC]
53. Kim YI, Shin HW, Chun YS, Cho CH, Koh J, Chung DH, et al. Epithelial cell-derived cytokines CST3 and GDF15 as potential therapeutics for pulmonary fibrosis. Cell Death Dis 2018;9:506
[CROSSREF] [PUBMED] [PMC] [PDF]
54. Emmerson PJ, Wang F, Du Y, Liu Q, Pickard RT, Gonciarz MD, et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat Med 2017;23:1215-1219.
[CROSSREF] [PDF]
55. Mullican SE, Lin-Schmidt X, Chin CN, Chavez JA, Furman JL, Armstrong AA, et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med 2017;23:1150-1157.
[CROSSREF] [PUBMED] [PDF]
56. Yang L, Chang CC, Sun Z, Madsen D, Zhu H, Padkjaer SB, et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat Med 2017;23:1158-1166.
[CROSSREF] [PUBMED] [PDF]
57. Gariani K, Ryu D, Menzies KJ, Yi HS, Stein S, Zhang H, et al. Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease. J Hepatol 2017;66:132-141.
[CROSSREF] [PUBMED]
58. Fiorese CJ, Schulz AM, Lin YF, Rosin N, Pellegrino MW, Haynes CM. The transcription factor ATF5 mediates a mammalian mitochondrial UPR. Curr Biol 2016;26:2037-2043.
[CROSSREF] [PUBMED] [PMC]